Company Profile
HCW Biologics Stock Price, News & Catalysts
- Ticker:
- HCWB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.52 USD (-5.97%)
Close
Last updated: August 17, 2026
12.8M USD
Market cap
Why the stock is moving
Following the latest company update, âHCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Resultsâ, HCWB closed down 8.38% at $2.68 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Fusion Immunotherapeutics
HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune disease, cancer, and conditions associated with chronic inflammation and cellular senescence. Its pipeline is built around engineered cytokine and multispecific immune-cell engagement technologies.
HCW9302 Treg Program
HCW9302 is an IL-2-based fusion molecule designed to engage CD25 and expand regulatory T cells. The candidate is in a Phase 1 monotherapy study in alopecia areata, with the company evaluating its ability to restore immune balance without broadly suppressing immune function.
HCW11-018b T-Cell Engager
HCW11-018b is a tetravalent T-cell engager generated from the company's proprietary TRBC platform. It is designed to direct CD3-positive effector T cells toward tissue factor-expressing solid tumors while countering immunosuppressive features of the tumor microenvironment.
Cell-Therapy Manufacturing Reagents
HCW9206 is a commercial-ready reagent intended for use in CAR-T cell manufacturing. The program is designed to promote memory stem-cell characteristics that may improve cell persistence and function while supporting more efficient manufacturing processes.
Future catalysts
- Full Phase 1 data for HCW9302 in alopecia areata in Q4 2026.
- Initiation of a clinical trial of HCW11-018b in solid tumors in the first half of 2027, subject to FDA authorization.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of HCW Biologics (HCWB)?
HCW Biologics (HCWB) most recently closed at 2.52 USD, a -5.97% move versus the previous session.
What is the market cap of HCW Biologics (HCWB)?
HCW Biologics currently has a market capitalization of 12.8M USD on BioPharmSignal.
What does HCW Biologics do?
Fusion Immunotherapeutics HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune disease, cancer, and conditions associated with chronic inflammation and cellular senescence. Its pipeline is built around engineered cytokine and multispecific immune-cell engagement technologies. HCW9302 Treg...
On which exchange is HCWB stock listed?
HCW Biologics (HCWB) is associated with NASDAQ, United States, Biopharma.
What is IL-2?
HCW9302 Treg Program HCW9302 is an IL-2-based fusion molecule designed to engage CD25 and expand regulatory T cells.
Which conditions is HCW Biologics targeting with IL-2?
HCW Biologics is associated with cancer therapeutics, inflammatory disease based on its company overview and current catalyst commentary.
How does HCW Biologics describe recent progress with IL-2?
Full Phase 1 data for HCW9302 in alopecia areata in Q4 2026. Initiation of a clinical trial of HCW11-018b in solid tumors in the first half of 2027, subject to FDA authorization.
What is CAR-T?
Cell-Therapy Manufacturing Reagents HCW9206 is a commercial-ready reagent intended for use in CAR-T cell manufacturing.